Date: 2012-05-08
Type of information: Grant
Company: Lanthio Pharma (The Netherlands)
Investors: SNN (The Netherlands) - Province of Groningen (The Netherlands)
Amount: €176,000
Funding type: grant
Planned used:
Others: Lanthio Pharma, a Dutch peptide drug discovery company, has announced today that a Project proposal in collaboration with the University of Groningen has been awarded a grant of €121,000 from SNN and €55,000 from the Province of Groningen. The Project concerns a 2 year collaboration of Lanthio Pharma with the Molecular Genetics Department, University of Groningen. Goal of the Project is to develop the technology to enzymatically introduce larger intramolecular bridges in peptide therapeutics. This will expand the possibilities to generate therapeutics with highly specific receptor interaction and good drug-like properties due to resistance to breakdown by peptidases. In particular the technology will enable to stabilize alpha helix structures, which are important for receptor interactions.
Therapeutic area: Technology - Services
